Direct answer
Amgen competes against AbbVie, Regeneron, Roche, and Eli Lilly, but the overlap is not identical across every product or customer. The useful question is which profit pool is contested, which customer can switch, and what advantage is required to win.
AbbVie
AbbVie overlaps with Amgen in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate AbbVie versus Amgen across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Regeneron
Regeneron overlaps with Amgen in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Regeneron versus Amgen across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Roche
Roche overlaps with Amgen in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Roche versus Amgen across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Eli Lilly
Eli Lilly overlaps with Amgen in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Eli Lilly versus Amgen across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.
Competitive dimensions that matter
| Dimension | Question for Amgen |
|---|---|
| Product | Does Amgen's offering solve the customer problem better or more completely? |
| Price | Is pricing supported by differentiated value or merely by a favorable cycle? |
| Distribution | Can competitors reach the same customers with similar efficiency? |
| Switching cost | What economic, technical or organizational friction makes a change difficult? |
| Scale | Does scale lower cost, improve data, expand selection or support larger R&D budgets? |
| Capital intensity | How much cash must be committed to defend the position? |
| Innovation | Is product leadership sustained through measurable adoption and outcomes? |
| Regulation | Does regulation protect incumbents, raise cost, or create disruption risk? |
How to tell whether the moat is strengthening
Do not label the company as having a "wide moat" without evidence. For Amgen, look for a combination of improving product sales by franchise, R&D, and operating margin, resilient customer behavior and favorable movement in prescription volume, and pricing. If the company must continually cut price, overspend to retain customers or accept weaker returns, scale alone may not represent an advantage.
Competitive warning signs
Competitive erosion can appear before revenue declines. Watch for slower adoption, weaker renewal or repeat activity, price concessions, increased customer acquisition cost, rising R&D just to maintain parity, loss of strategic partners, or a competitor setting the pace of the product roadmap.
The relevant warning signs for Amgen should be mapped to patent loss, clinical failures, pricing pressure, regulation, and acquisition integration.